RICHARD N KOLESNICK, MD
Osteopathic Medicine at York Ave, New York, NY

6040149, Mar 21, 2000

Jan 10, 1997

8/785247

Richard N. Kolesnick - New York NY
Jun Liu - Boston MA
Yuhua Zhang - New York NY

Sloan-Kettering Institute for Cancer Research - New York NY

C12Q 148, C12N 912, A61K 3851

435 15

The subject invention provides a purified membrane-bound ceramide-activated protein kinase having an apparent molecular weight of about 110 kD as determined by SDS polyacrylamide gel electrophoresis, which protein kinase is capable of specifically phosphorylating the threonine residue in a Thr-Pro- or a Thr-Leu-Pro-containing polypeptide. The subject invention also provides a method of determining whether an agent is capable of specifically inhibiting the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of determining whether an agent is capable of specifically stimulating the phosphorylation activity of the ceramide-activated protein kinase. The subject invention further provides a method of treating a subject having an inflammatory disorder. The subject invention further provides a method of treating a human subject infected with HIV so as to reduce the proliferation of HIV in the human subject.

8562993, Oct 22, 2013

May 6, 2008

12/599280

Jimmy Andrew Rotolo - New York NY, US
Richard Kolesnick - New York NY, US
Renata Pasqualini - Houston TX, US
Wadih Arap - Houston TX, US

Board of Regents the University of Texas System - Austin TX
Sloan Kettering Institute for Cancer Research - New York NY

A61K 39/395

4241451, 4241411, 4241421, 4241301

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

7850984, Dec 14, 2010

Aug 12, 2002

10/217259

Jonathan L. Tilly - Windham NH, US
Richard N. Kolesnick - New York NY, US

The General Hospital Corporation - Boston MA
Memorial Sloan-Kettering Cancer Center - New York NY

A61F 2/02

424423

Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.

8258108, Sep 4, 2012

Oct 12, 2007

11/974473

Richard N. Kolesnick - New York NY, US
Hongmei R. Xing - New York NY, US

Memorial Sloan-Kettering Cancer Center - New York NY

C12N 15/11

514 44A

The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.

8283459, Oct 9, 2012

Oct 12, 2007

11/974481

Richard N. Kolesnick - New York NY, US
Hongmei R. Xing - New York NY, US

Memorial Sloan-Kettering Cancer Center - New York NY

C07H 21/04

536 245

The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.

7195775, Mar 27, 2007

Feb 15, 2000

09/503852

Jonathan L. Tilly - Windham NH, US
Richard N. Kolesnick - New York NY, US

The General Hospital Corporation - Boston MA

A61F 6/00, A01N 57/00

424430, 514114

Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.

2007015, Jul 5, 2007

Mar 7, 2007

11/715795

Johnathan Tilly - Windham NH, US
Richard Kolesnick - New York NY, US

Massachusetts General Hospital, Partners HealthCare Research Ventures & Licensing - Boston MA

A01K 67/027

800021000, 424093700

Described are methods for protecting the female reproductive system against natural and artificial insults by administering to women a composition comprising an agent that antagonizes one or more acid sphingomyelinase (ASMase) gene products. Specifically, methods disclosed herein serve to protect women's germline from damage resulting from cancer therapy regimens including chemotherapy or radiotherapy. In one aspect, the method preserves, enhances, or revives ovarian function in women, by administering to women a composition containing sphingosine-1-phosphate, or an analog thereof. Also disclosed are methods to prevent or ameliorate menopausal syndromes and to improve in vitro fertilization techniques.

6274309, Aug 14, 2001

Jul 26, 1996

8/687707

Richard Kolesnick - New York NY
Edward H. Schuchman - Haworth NJ

C12Q 102, C12Q 118, C12Q 142, C12Q 168

435 6

The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i. e. , either increase or decrease) sensitivity to ASM-related processes, including apoptosis.

5451518, Sep 19, 1995

Nov 13, 1992

7/976378

Richard N. Kolesnick - New York NY

Sloan-Kettering Institute for Cancer Research - New York NY

C12N 912, C12Q 148, A61K 3845

435194

A membrane-bound ceramide-activated protein kinase has been purified from human cells. The protein kinase has an apparent molecular weight of about 95 kD and specifically phosphorylates the threonine residue in a polypeptide containing Pro-Leu-Thr-Pro (SEQID NO:1).